Skip to main content
Clinical Trials/NCT05215964
NCT05215964
Unknown
Not Applicable

The Association Between Skeletal Muscle Mass and Severity of Polycystic Liver Disease and Polycystic Kidney Disease

National Taiwan University Hospital1 site in 1 country600 target enrollmentSeptember 29, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Polycystic Kidney Diseases
Sponsor
National Taiwan University Hospital
Enrollment
600
Locations
1
Primary Endpoint
Total psoas muscle change
Last Updated
4 years ago

Overview

Brief Summary

Primary sarcopenia is used to describe aging and progressed with the physiologic decline. Secondary sarcopenia is associated many chronic disease, including acquired immune deficiency syndrome, cancer, chronic heart failure, chronic lung disease, liver cirrhosis, chronic kidney disease and rheumatoid arthritis. In the past, nutrition status is evaluated by body mass index, mid-upper -arm circumference and serum albumin. Bioelectrical impedance analysis is also a common method to measured body composition, but bioelectrical impedance analysis will be affected by tissue edema and ascites. In contrast, cross-section imaging, such as computed tomography and magnetic resonance can analyzed abdominal muscle and fat accurately.

Since computed tomography and magnetic resonance imaging can evaluate the severity of polycystic liver and kidney disease. Investigators can use cross section imaging at 3rd lumber level to separate skeletal muscle and fat tissue. Previous studies showed the quantity and quality of abdominal muscle are important prognostic factor after liver transplantation. Besides, chronic kidney disease and receiving renal placement therapy lead protein catabolism and make patients with end stage renal disease have sarcopenia. Finally, patients with polycystic liver and kidney disease have organomegaly, which causes abdominal distention and poor appetite. Therefore, the aim of this study is to observe the association between skeletal muscle mass and the severity of disease and to study whether change in hepatic and renal volumes is associated with change in muscle mass.

Detailed Description

The imaging study (CT or MRI) will be performed within one month before the procedure to measure total kidney volume and psoas muscle area. The procedure will use transcatheter embolization to renal artery. The follow-up imaging study will be performed six months after the procedure to measure total kidney volume and psoas muscle area..

Registry
clinicaltrials.gov
Start Date
September 29, 2020
End Date
December 31, 2023
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Polycystic related disease with medical images (CT or MRI) diagnosed
  • Aged over 20 years

Exclusion Criteria

  • Lack of Bio-exam or medical images
  • Pregnancy

Outcomes

Primary Outcomes

Total psoas muscle change

Time Frame: 6 months by imaging study

The change of psoas muscle area before and after procedures.

Secondary Outcomes

  • Total kidney volume change(6 months by imaging study)

Study Sites (1)

Loading locations...

Similar Trials